Skip to content
    Clinical Trials

    Fatigue and Nausea Are the Most Prevalent Toxicities With Trastuzumab Deruxtecan

    Cazzaniga et alSupportive Care in Cancer

    Fatigue and Nausea Are the Most Prevalent Toxicities With Trastuzumab Deruxtecan
    Trastuzumab deruxtecan (T-DXd) has shown remarkable efficacy in phase III trials for HER2-positive early- and late-stage breast cancer, as well as HER2-low and ultra-low metastatic breast cancer (mBC). However, adverse events remain clinically relevant and frequently prompt dose interruptions, dose reductions, or treatment discontinuations. To characterize real-world management strategies, the Hermione EDUcational project conducted a survey among 99 oncology experts spanning 13 countries worldwide, focusing on nausea and vomiting, fatigue, and interstitial lung disease (ILD).
    Survey results revealed that fatigue and nausea were the most prevalent toxicities, reported by 94.9% and 91.9% of respondents, respectively. Fatigue was observed in more than 60% of patients by 65% of surveyed oncologists, and respondents largely reported that both fatigue and nausea/vomiting moderately or significantly impaired patient quality of life and activities of daily living. For nausea prophylaxis, clinicians most frequently administered a three-drug regimen comprising an NK1 receptor antagonist, a 5-HT3 receptor antagonist, and corticosteroids, though utilization of second-generation 5-HT3 antagonists varied. In addition, 44% of clinicians escalated to a four-drug regimen containing olanzapine and an NK1 receptor antagonist for patients experiencing nausea or vomiting above grade 1 in cycle one, whereas 35% reserved this four-drug strategy for high-risk patients, and 21% administered it to all patients starting from cycle one.
    ILD was described by respondents as rare or occasional and was primarily monitored utilizing computed tomography imaging. Based on these survey findings, managing T-DXd-related toxicities in clinical practice is complex, necessitating comprehensive longitudinal evaluation before, during, and after therapy alongside a skilled multidisciplinary care team.

    Key Takeaways

    • In a worldwide survey of 99 oncologists across 13 countries, nausea and fatigue were the most frequently encountered adverse events during trastuzumab deruxtecan therapy, reported by 91.9% and 94.9% of respondents, respectively, with 65% observing fatigue in more than 60% of patients.
    • For antiemetic prophylaxis, oncologists most frequently employed a triplet regimen of 5-HT3 receptor antagonists, NK1 receptor antagonists, and corticosteroids, while four-drug regimens incorporating olanzapine were used upfront for all patients by 21%, reserved for high-risk patients by 35%, and initiated after grade >1 nausea/vomiting in cycle 1 by 44%.
    • Interstitial lung disease was reported as rare or occasional and was generally monitored with computed tomography, while both nausea/vomiting and fatigue were judged by most clinicians to moderately or significantly impair daily activities and quality of life.
    Read the original sourceSupportive Care in Cancer